Angus Worthing, MD, FACR, FACP, clarifies key biosimilars terms.
Transcript:
Interchangeability, switching, substitution: there seems to be some confusion about these terms. Can you clarify?
Switching and substitution both refer to the process of moving from one drug to another; for example, from a biologic reference drug to a biosimilar drug. Substitution refers to the specific process in which a pharmacist receives a prescription from the doctor for one drug, for example the reference biologic. But instead of dispensing that drug, instead it dispenses a biosimilar drug or a different medication that has been FDA approved as an interchangeable drug. That pharmacist is in a state or jurisdiction in which that process has been regulated and laws have been put in place. So, the patient ultimately receives, for example, the biosimilar drug after the prescription was written for the reference biologic. In contrast, switching refers to a prescription being changed. So a physician, for example, is treating a patient with the reference biologic and instead decides—and usually we anticipate with the patient—to write a prescription for the biosimilar and then that prescription goes to the pharmacy and the pharmacist dispenses the biosimilar. Interchangeability is the condition of a biosimilar that makes it legal for the pharmacist in certain jurisdictions, to make a substitution and that’s a process that’s being developed right now at the FDA. FDA has issued what we, at the American College of Rheumatology feel are very good guidances about how to design a clinical trial to prove that a drug can be substituted—or in other words, that a drug in interchangeable with a reference biologic—because the clinical trial design involves switching back and forth and alternating 3 times from the reference drug to the biosimilar, back to the reference drug, then back to the biosimilar. So, 3 switches, and then deciding that the drug is safe and effective at the end of that process.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.